Mayne Pharma Group Limited (MAYNF)
OTCMKTS · Delayed Price · Currency is USD
3.515
0.00 (0.00%)
At close: Jul 21, 2025
Mayne Pharma Group Revenue
Mayne Pharma Group had revenue of 213.05M AUD in the half year ending December 31, 2024, with 307.91% growth. This brings the company's revenue in the last twelve months to 413.53M, up 64.47% year-over-year. In the fiscal year ending June 30, 2024, Mayne Pharma Group had annual revenue of 388.40M with 111.56% growth.
Revenue (ttm)
413.53M AUD
Revenue Growth
+64.47%
P/S Ratio
1.09
Revenue / Employee
427.64K AUD
Employees
967
Market Cap
279.74M USD
Revenue Chart
* This company reports financials in AUD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Jun 30, 2024 | 388.40M | 204.81M | 111.56% |
Jun 30, 2023 | 183.59M | 26.44M | 16.82% |
Jun 30, 2022 | 157.15M | -243.63M | -60.79% |
Jun 30, 2021 | 400.78M | -56.20M | -12.30% |
Jun 30, 2020 | 456.99M | -68.22M | -12.99% |
Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo, Inc. | 1.73B |
Veradigm | 588.02M |
Tian'an Technology Group | 1.78M |
Elite Pharmaceuticals | 84.04M |
Glass House Brands | 215.62M |
Northwest Biotherapeutics | 1.47M |
American Oncology Network | 1.76B |
Silence Therapeutics | 27.70M |
Mayne Pharma Group News
- 8 days ago - Jefferies, Mayne Pharma in spotlight in after suitor’s court win - The Australian Financial Review
- 16 days ago - Hedge fund bets US suitor won’t get out of Mayne Pharma takeover - The Australian Financial Review
- 6 weeks ago - Proxy advisers support Mayne Pharma deal as suitor tries to exit - The Australian Financial Review
- 7 weeks ago - Cosette terminates $672m Mayne Pharma deal as legal challenge looms - The Australian Financial Review
- 2 months ago - Why a private equity group is rethinking its bid for Mayne Pharma - The Australian Financial Review
- 2 months ago - Mayne Pharma slumps 30% as Cosette threatens to scrap $432 million deal - Reuters
- 2 months ago - Mayne Pharma shares crash after suitor Cosette raises concerns - The Australian Financial Review
- 2 months ago - Mayne Pharma shares crash after suitor Cosette threatens to walk - The Australian Financial Review